Tests CR-002 in adults with advanced solid tumors
Tests the safety of CR-002 in adults with several advanced solid cancers.
Key facts
- Who runs it
- Crescent Biopharma, Inc.
- Where
- Austin, Dallas, and Fairfax, United StatesSee the 3 sites
- Trial code
- Registry title
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 219 people, planned
- Started
- 21 Oct 2026
- Expected to end
- Jan 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- CR-002
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or spreading solid tumors of certain types who have run out of standard treatment options.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Locally advanced or metastatic cancer of one of these types: head and neck squamous cell, gastric/GEJ, biliary tract, esophageal squamous cell, ovarian, endometrial, cervical, or non-small cell lung. The disease must be measurable by RECIST v1.1. The cancer is getting worse on, cannot be treated with, or has no available local standard treatment.
- Earlier treatment
- Must have progressed on, not tolerated, or be unable to receive local standard treatments. Must not have had an antibody-drug conjugate with a topoisomerase I inhibitor payload.
Main reasons for not taking part
- Another cancer within the past 3 years
- Active cancer spread to the brain or spinal cord (CNS metastases)
- Earlier treatment with an antibody-drug conjugate with a topoisomerase I inhibitor payload
- Not recovered from recent major surgery, or ongoing serious side effects from earlier treatment
- Known sensitivity to any component of CR-002
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Life expectancy ≥ 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
- Adequate organ function and hematologic reserve based on laboratory parameters
- Have measurable disease defined by RECIST v1.1
- Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy
- Tumor indication specific inclusion criteria:
- Is progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have one of the following locally advanced or metastatic tumor types:; Head and Neck Squamous Cell Carcinoma (HNSCC); Gastric/GEJ Cancer; Biliary Tract Cancer (BTC); Esophageal Squamous Cell Carcinoma (ESCC); Ovarian Cancer; Endometrial Carcinoma; Cervical Cancer; Non-Small Cell Lung Cancer (NSCLC)
Who cannot take part
- Has not adequately recovered from recent major surgery
- Has ongoing clinically significant toxicity related to prior therapy
- Has received prior treatment with an antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload
- Has malignancies other than disease under study within the past 3 years
- Has a medical or psychological condition that could interfere with study participation, increase risk, or affect interpretation of the study results
- Has known sensitivity to any component of CR-002
- Has active central nervous system (CNS) metastases
- NOTE: Other protocol defined Inclusion and Exclusion criteria may apply
Where in United States
- Austin, TexasHospital not named in the registryContact: Crescent Clinical TrialsTaking people
- Dallas, TexasHospital not named in the registryContact: Crescent Clinical TrialsTaking people
- Fairfax, VirginiaHospital not named in the registryContact: Crescent Clinical TrialsTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
The 2 groups in the trial
- CR-002 Dose EscalationTreatment being tested
Escalating dose levels of CR-002 will be tested to define the maximum tolerated dose of CR-002 in participants with locally advanced or metastatic solid tumors who are refractory to or unable to tolerate standard of care treatment, or for whom standard of care treatment is unavailable.
Treatment: CR-002
- CR-002 BackfillTreatment being tested
Escalating dose levels of CR-002 will be tested in indication-specific cohort populations.
Treatment: CR-002
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Plain-language title
- Tests CR-002 in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 2 November 2026